source
- Merck and Moderna report positive late-stage melanoma vaccine results, adding to 2026 cancer breakthrough yearMerck and Moderna announced that their personalized mRNA neoantigen vaccine achieved positive outcomes in a late-stage trial for melanoma patients. The data suggest the vaccine can stimulate an imm…
- Neumora Therapeutics appoints Joshua Pinto as CEO and Doron Sagman as CMO ahead of IND filingNeumora Therapeutics announced leadership changes, naming Joshua Pinto, Ph.D., as its new chief executive officer. Pinto, who joined Neumora in 2021 as chief financial officer and most recently se…